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ABSTRACT The neuropoietic cytokine cholinergic differ-
entiation factor/leukemia nhibitory factor (CDF/LIF) acts as
a trophic factor, enhancing neuronal survival, and as a differ-
entiation factor, altering neuronal gene expression. There Is
also evidence that It plays a role in the response of adult neural
tissue to inJury. We have exaied this possibility further in
rats by analyzing changes in the levels ofmRNAs for CDF/LIF
and its two receptor subunits in response to peripheral nerve
damage in culture and in vivo. Using a quantitative RNase
protection assay, we find that CDF/LIF mRNA increases
dramatically (176-fold) in adult, but not neonatal, sympathetic
ganglia and in adult dorsal root ganglia and sciatic nerve after
organ culture for 24 hr. This mRNA is clearly detectable by in
situ hybridization only in the nonneuronal cells of these struc-
tures. When the sciatic nerve is trinsected in vivo, CDF/LIF
mRNA increases sgnlfcantly in the regions Immediatel prox-
imal and distal to the lesion site. The mRNA for the igand
binding subunit of the CDF/LIF receptor complex decreases
somewhat upon culture and nerve section. The dramatic rise in
CDF/LIF mRNA after nerve injury is further evidence that
this cytokine is involved in the response to damage, a function
that overlaps with its postulated role in wounding or infection
in several nonneural tissues.
Mammalian peripheral nerves can regenerate after injury.
They also participate in the response to damage of other
tissues, such as the inflammatory reaction in arthritis (1).
Both the response to nerve injury and the generation of an
inflammatory reaction involve a complex cascade of signals
among neuronal axons, glia, and cells of the immune system.
Much of this communication is mediated by cytokines/
interleukins (ILs) and by neurotransmitters and neuropep-
tides released by neurons and possibly the immune cells.
Prime candidates for involvement in these events are the
neuropoietic cytokines, an emerging family of proteins
grouped not by extensive sequence identity but rather by
redundancies in biological effects on cells of the nervous and
hematopoietic systems, by the sharing of receptor subunits,
and by predicted secondary structures (2-4). Members ofthis
family recognized thus far include cholinergic differentiation
factor/leukemia inhibitory factor (CDF/LIF), ciliary neuro-
trophic factor (CNTF), oncostatin M, growth promoting
activity, IL-6, and IL-il (4). All of these cytokines can
regulate gene expression in peripheral neurons, and four of
them have also been shown to exert trophic effects on various
types of peripheral and central neurons (for review, see ref.
5).
A striking feature of the neuropeptides induced in cultured
neonatal sympathetic neurons by CDF/LIF, CNTF, oncos-
tatin M, and growth promoting factor is that several of these
same neuropeptides are also induced in adult sympathetic
neurons when the ganglia are damaged by explantation in
short-term culture or by axotomy in vivo. For instance,
substance P and vasoactive intestinal polypeptide (VIP) are
induced both by nerve damage and by application of these
neuropoietic cytokines to pure neuronal cultures (4, 6, 7). In
response to peripheral nerve damage, VIP is induced in
dorsal root ganglia (DRGs) as well (8, 9). Moreover, CDF/
LIF elevates VIP in dissociated DRG neurons (10). Part of
the in vivo response to injury could be mediated by nonneu-
ronal cells in the ganglia, since these cells have been shown
to release CDF/LIF (11, 12). CDF/LIF involvement in the
neuropeptide response to nerve damage is further indicated
by results from mice in which the CDF/LIF gene was
disrupted by homologous recombination. Ganglia from such
mutant mice display a much reduced neuropeptide response
to culturing or axotomy (13).
To further investigate the role of CDF/LIF in the events
surrounding nerve damage, we have determined whether the
levels of CDF/LIF and its receptor subunits change after
nerve and ganglion injury. The major sources of CDF/LIF
mRNA under these conditions were also localized by in situ
hybridization. Some of these findings have been reported
(14-16).
MATERIALS AND METHODS
Surgical Procedures and Organ Culture. Adult male and
female rats were anesthetized by intraperitoneal injection of
sodium pentobarbitol (Nembutol, Abbott; 40 mg/kg). The
sciatic nerve was exposed and transected. To ensure that
regeneration did not occur, a 3-mm piece of the nerve was
removed and the remaining ends were deflected. Care was
taken so that surrounding muscles were not damaged. The
wound was closed with clips. Each time point is composed of
data from nerves of nine animals. At the appropriate time,
animals were killed by CO2 inhalation and various regions of
the sciatic nerve were dissected and frozen at -700C. Cor-
responding regions of nerve were removed from the contra-
lateral side of each rat as control.
Fifteen superior cervical ganglia (SCGs) from postnatal
day 1 (PI) rats and 15 adult DRGs and 10 SCGs from adult
Sprague-Dawley (Simonson Laboratories, Gilroy, CA) rats
were dissected, desheathed, and placed in organ culture.
Ganglia were maintained in L15/CO2 medium (17) supple-
mented with 5% (vol/vol) rat serum and nerve growth factor
(NGF; 100 ng/ml) for 24 hr. Sciatic nerves from three adult
animals were dissected, cut into sections ~1 cm long, and
Abbreviations: CNTF, ciliary neurotrophic factor; CDF/LIF, cho-
linergic differentiation factor/leukemia inhibitory factor; DRG, dor-
sal root ganglion; GAPDH, glyceraldehyde phosphate dehydroge-
nase; GPA, gpl30, glycoprotein 130; LIFR, LIF receptor; NGF,
nerve growth factor; P1 postnatal day 1; SCG, superior cervical
ganglion; IL, interleukin; VIP, vasoactive intestinal polypeptide.
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maintained under the same conditions as the ganglia. After
culture, tissues were frozen at -700C prior to RNA extrac-
tion. Each ofthe above experiments was performed twice. As
controls, equal numbers ofganglia and nerves were dissected
and frozen immediately at -700C.
RNA Extraction and RNase Protection Assay. Total RNA
was extracted from the tissues by the acid-phenol method
(18). RNA was resuspended in distilled H20 and stored at
-700C. RNase protection analysis was performed as de-
scribed (19). A portion ofLIF receptor (LIFR), glycoprotein
130 (gp130), and glyceraldehyde phosphate dehydrogenase
(GAPDH) cDNAs from rat kidney were isolated by the
polymerase chain reaction (PCR). The PCR products were
ligated into Bluescript KS (Stratagene) and sequenced to
confirm their identity. The cDNAs were linearized and
32P-labeled sense RNA generated by in vitro transcription
was hybridized to tissue RNAs. The probes yielded protected
fiagments of 397 nucleotides for LIFR, 120 nucleotides for
GAPDH, 451 nucleotides for gpl30, and 169 nucleotides for
CDF/LIF (19). Radioactivity was quantitated by scanning
the protected fragments on a Phosphorlmager 400S (Molec-
ular Dynamics). The intensities of the protected fiagments
corresponding to LIF, LIFR, and gpl30 were compared to
the GAPDH protected fragment as an internal control for the
amount of RNA, and the values are expressed in arbitrary
units. Control RNase protection experiments with known
amounts of in vitro-transcribed sense RNA probes deter-
mined that the values obtained for each scan are within the
linear range of the PhosphorImager. GAPDH levels mea-
sured before and after nerve transection revealed that the
mRNA forGAPDH did not change significantly after transec-
tion.
In Situ Hybridization Antisense and sense digoxigenin-
labeled CDF/LIF probes were generated using the Ambion
(Austin, TX) MEGAscript in vitro transcription kit. In situ
hybridization was performed as described (20). Briefly,
20-pm sections of fixed cultured ganglia and nerve were
hybridized overnight at 500C with sense or antisense probes,
either probe at 1-2 ug/ml. After RNase digestion, sections
were incubated with an anti-digoxigenin antibody (Boehring-
er Mannheim) and the alkaline phosphatase reaction product
was visualized with nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate.
RESULTS
Changes in the mRNAs for CDF/LIF and Its Receptor
Subunits After Organ Culture of the SCGs. To determine
whether CDF/LIF mRNA changes in sympathetic ganglia in
response to injury, neonatal (P1) and adult SCGs were placed
in organ culture. After 24 hr, CDF/LIF mRNA was analyzed
using a quantitative RNase protection assay. To standardize
the CDF/LIF mRNA values, they were expressed as a ratio
to GAPDH, an internal control for total RNA. This ratio also
controls for variability in RNA recovery from the tissues, and
since the GAPDH sample is quantified in the same sample
and gel lane, it controls for variability in processing of the
samples. Moreover, GAPDH levels were found not to be
altered by nerve damage (see below).
There was a 10-fold induction in the expression of CDF/
LIFmRNA relative to GAPDH mRNAwhen P1 ganglia were
cultured for 24 hr (Fig. 1A). CDF/LIF mRNA levels in-
creased even more dramatically, however, when adult SCGs
were placed in organ culture for 24 hr; the increase was
176-fold over levels in uncultured ganglia (Fig. 1A). The
enormous increase in CDF/LIF mRNA after organ culture of
adult ganglia was not paralleled by similar changes in its
receptor mRNA expression. The levels of the ligand binding
receptor subunit, LIFR, decreased by halfin both cultured P1
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FIG. 1. Expression of mRNAs for CDF/LIF and its receptor in
SCGs after 24 hr in organ culture. Ganglia were removed from
neonatal (P1) and adult (A) rats and frozen directly at -70TC (bars P1
and A) or placed in organ culture for 24 hr (bars P1 culture and A
culture). Data are the mean ± SEM (n = 4 for each point). (A)
Expression ofCDF/LIFmRNA as assayed by RNase protection and
expressed relative to GAPDH. (B) Expression ofthe mRNAs for the
two CDF/LIF receptor subunits, LIFR and gp130.
Expression of the transducing subunit, gp130, remained
essentially the same in both P1 and adult SCGs after organ
culture for 24 hr (Fig. 1B).
Expression of CDF/LIF mRNA In Sensory Ganglia and
Peripheral Nerve After Organ Culture. As outlined above,
motor and sensory neurons are also known to up-regulate
certain neuropeptides after injury. To determine whether
CDF/LIF mRNA levels change in response to sensory
ganglion injury, adult DRGs were cultured for 24 hr and
expression of CDF/LIF mRNA was monitored. As is the
case for adult sympathetic ganglia, relatively low levels of
CDF/LIF mRNA were present in normal adult sensory
ganglia. After culture for 24 hr, however, the levels increased
43-fold (Fig. 2A), indicating that the CDF/LIF induction is
not unique to the SCG. LIFR mRNA also showed a response
similar to that of the SCG (Fig. 2B), decreasing slightly after
culture, whereas gp130mRNA levels remained constant. It is
important to note that GAPDH levels measured before and
after nerve transection revealed that the mRNA for GAPDH
did not change significantly after transection (data not
shown).
The large difference in the inducibility of CDF/LIF be-
tween P1 and adult sympathetic ganglia (Fig. 1) could be due
to the increase in the number of glial cells that occurs during
postnatal development. To examine the CDF/LIF response
in a tissue composed primarily of glial cells, we examined the
effects of organ culture on adult sciatic nerve. In response to
24 hr of organ culture, the expression of CDF/LIF mRNA
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FIG. 2. Expression of mRNAs for CDF/LIF and its receptor in
adult DRGs after 24 hr in organ culture. Ganglia from adult rats were
removed and frozen directly (0 hr) or placed in organ culture for 24
hr. Data are the mean + SEM (n = 3). (A) Regulation of CDF/LIF
mRNA in response to organ culture. (B) Expression of LIFR and
gpl3O mRNAs.
Proc. Natl. Acad. Sci. USA 91 (1994)
Proc. Natl. Acad. Sci. USA 91 (1994) 7111
= 18 6






0 5 10 15
days after transection
ir 24 hr Ohr 24hr
FIG. 3. Expression of mRNAs for CDF/LIF and its receptor in
adult sciatic nerve after 24 hr in organ culture. Sciatic nerve was
removed from adult rats, cut into '1-cm pieces, and frozen directly
(O hr) or placed in organ culture for 24 hr. Data are the mean ± SEM
(n = 3 or 4). (A) Expression ofCDF/LIF mRNA. (B) Expression of
LIER and gp13O mRNAs.
mRNA decreased 4-fold after organ culture, whereas gp130
levels remained constant (Fig. 3B).
CDF/LIF mRNA In Adult Sdatic Nerve Is Up-Regulated In
Response to Transection in Vivo. The pronounced increase in
CDF/LIF mRNA expression in sciatic nerve after 24 hr of
culture led us to investigate whether CDF/LIF might be
regulated in a similar manner in vivo. Adult rat sciatic nerves
were transected at mid-thigh level and CDF/LIF mRNA
from different portions of the nerve was monitored from 24
hr to 14 days after transection. Three regions-immediately
distal to the transection site (distal), immediately proximal to
the transection site (proximal-1), and a second proximal
portion, adjacent to proximal-i but closer to the spinal cord
(proximal-2), each 1 cm long-were examined by RNase
protection analysis. As with cultured sciatic nerve, there was
an increase in CDF/LIF expression, although the in vivo
increase was not as dramatic as in organ culture. Twenty-four
hours after transection, the mRNA for CDF/LIF was '11-
fold higher in the region distal to the transection site and
13-fold higher in the proximal-i region, when compared to
their respective undisturbed contralateral regions (Fig. 4). At
5 days after transection, the expression of CDF/LIF in the
distal and proximal-i regions remained higher than the con-
tralateral values. By 14 days after injury, the level of CDF/
LIF in the proximal-i region decreased while levels in the
distal region remained essentially the same as those seen at
7 days. CDF/LIF mRNA levels in the proximal-2 region
remained relatively unchanged throughout the 2-week pe-
riod.
The Lignd Binding Receptor Subunit for CDF/LIF De-







FIG. 4. Effect of sciatic nerve transection on CDF/LIF mRNA
expression in vivo. Sciatic nerve RNA from three regions, immedi-
ately distal (0) and immediately proximal (o), and a proximal region
closer to the spinal cord (A) was assayed for CDF/LIF at several
times after transection, in both transected (solid symbols) and
contralateral (open symbols) nerves. Each point represents RNA
from three groups of three animals, each group assayed one to three
times (mean ± SEM).
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FIG. 5. Effect of sciatic nerve transection on LIFR expression in
vivo (see Fig. 4 for explanation).
with the results seen when ganglia and nerve were cultured
for 24 hr (Figs. 1-3), LIFR levels in the region immediately
proximal and distal to the lesion site begin to decrease 24 hr
after transection (Fig. 5). This decrease continued until day
5 in the proximal-i region after which time the expression
returned to and exceeded those of the control values. Distal
to the transection site, LIFR mRNA levels were depressed
relative to control values throughout the entire 2-week period
studied. The levels of LIFR mRNA in the proximal-2 region
did not change relative to control values at any times exam-
ined (data not shown). There was a slight increase in the
expression of gpl30 in the distal and proximal-i regions but
the values did not differ significantly from those of the
contralateral regions (data not shown).
CDF/LIF Is Expessed In the Nonneuronal Cels of Periph-
eral Gangia and Nerve. While it has been known for many
years that CDF/LIF is produced by cultured nonneuronal
cells from ganglia, the identity of the cell type(s) responsible
has not been determined (11). Both fibroblasts and Schwann
cells can, however, secrete CDF/LIF in dissociated cell
culture (14, 21, 22). Because the mRNA for CDF/LIF is
present at very low levels in normal ganglia and nerve, our
attempts to determine which cells express it were unsuccess-
ful. Since the mRNA is greatly increased in response to organ
culture, however, we were able to observe cells strongly
positive for CDF/LIF mRNA by performing in situ hybrid-
ization on ganglia and sciatic nerve that had been cultured for
24 hr. The results of using digoxigenin-labeled antisense
CDF/LIF probes to hybridize with sections of adult SCGs
and sciatic nerve are illustrated in Fig. 6. In ganglia (Fig. 6A),
the staining was in small cells and not neurons. In sciatic
nerve (Fig. 6B), staining was in elongated cells, most ofwhich
appear to have processes on one or both ends; these mor-
phologies closely resemble Schwann cells. While the staining
is clearly nonneuronal in the ganglia, the precise identity of
the labeled cells is not certain. To determine whether the
CDF/LIF-positive cells were macrophages, we stained gan-
glia and nerve with macrophage-specific antibodies in con-junction with in situ hybridization for CDF/LIF mRNA. The
cells positive forCDF/LIFmRNA did not colocalize with the
macrophage-specific antibodies MUC-102 orOX42 (data not
shown).
DISCUSSION
The ability of the body to respond quickly and effectively to
damage is a crucial step in the recovery process, and the
release of cytokines by a variety of cell types plays a critical
role in the initial response to injury. We find that a member
of the neuropoietic cytokine family, active in both the. he-
matopoietic and nervous system, is dramatically up-
regulated in response to peripheral nerve damage. The in-
crease in CDF/LIF mRNA expression in the adult SCGs and
DRGs is consistent in time course and magnitude with the
changes in neuropeptide expression found in the ganglia after
injury. The lower CDF/LIF response in neonatal ganglia
suggests that the cell type that expresses it may be present in
fewer numbers or is less responsive in the neonate. The fact
Neurobiology: Banner and Patterson
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FIG. 6. In situ hybridization ofCDF/LIF. (A) Hybridization ofdigoxigenin-labeled antisense CDF/LIFmRNA probes to adult SCG cultured
for 24 hr. (B) Hybridization to cultured adult sciatic nerve. No hybridization was seen with sense control (data not shown). (Bar = 25 iam.)
that we find CDF/LIF expressed in nonneuronal cells of
ganglia and nerve is consistent with the fact that P1 ganglia
contain many fewer glial cells than adult ganglia.
CDF/LIF increases the survival of embryonic sensory
neurons in vitro (23) and was recently shown to be present in
vivo (24). This cytokine can also be retrogradely transported
to the sensory neurons of the DRG, suggesting a role for
CDF/LIF as a target-derived neurotrophic molecule for
sensory neurons (25). Further support for this notion is
derived from the observations that CDF/LIF rescues mo-
toneurons in culture and in vivo (26, 27) and is expressed in
embryonic muscle (19). On the other hand, we find that
during development, expression ofCDF/LIF mRNA and its
receptor increases from P1 to adulthood in many tissues,
indicating a role for the cytokine in normal homeostasis or
response to injury in the adult (15). The fact that CDF/LIF
mRNA is up-regulated in adult peripheral ganglia and sciatic
nerve suggests that CDF/LIF induction is a general phenom-
enon in response to injury of the peripheral nervous system.
Moreover, CDF/LIF mRNA is expressed in the adult brain
at higher levels than in the neonate (19), suggesting that it
might be involved in maintenance ofthe response to injury in
the central nervous system as well. In response to intraperi-
toneal injection of kainic acid, the CDF/LIF mRNA in-
creases in several brain regions (28). In addition, after
cortical brain lesions, CDF/LIF mRNA reaches a peak of
expression at 48 hr and returns to baseline values by 7 days
after the lesion (N. Moayeri, L.R.B. and P.H.P., unpublished
data).
The increase of CDF/LIF observed in vitro with sciatic
nerve explants was verified with in vivo nerve transections.
An increase of CDF/LIF mRNA occurs in the regions
immediately adjacent to the cut site, both proximal and distal.
This increase is rapid, occurring within 24 hr after injury, and
is maintained for at least 2 weeks. CDF/LIF mRNA levels in
the proximal-2 region do not change relative to control values
at any of the times examined, demonstrating that this aspect
of the injury response is highly localized. The initial rapid
increase in CDF/LIF mRNA expression is somewhat similar
to the induction ofNGF after sciatic nerve transection. NGF
mRNA levels increase dramatically within 6 hr in the regions
immediately proximal and distal to the lesion site. This initial
increase is followed, however, by a transient decrease be-
tween 12 and 24 hr and then by another increase in expression
that peaks at 3 days (29). Although we did not examine the
response of CDF/LIF 6 hr after transection, we observe a
dramatic increase in mRNA expression within 24 hr. The fact
that both CDF/LIF and NGF increase rapidly could be
related to the observation that both cytokines are inducible
by IL-1. The increase in NGF mRNA after sciatic nerve
transection is due to the expression of IL-1 by macrophages
that invade the lesion site (30). IL-1 also induces the expres-
sion of CDF/LIF in cultured ganglia (12). Although the
low-affinity (p75) NGF receptor is up-regulated in Schwann
cells in the region ofdegeneration (31), we find that the ligand
binding subunit of the CDF/LIF receptor complex decreases
somewhat after nerve injury. t
The pattern of CDF/LIF induction is distinctly different
from the pattern of another member of the neuropoietic
cytokine family, CNTF, that has also been suggested to be
involved in the response to injury. Like CDF/LIF, CNTF is
normally present in Schwann cells of the sciatic nerve (32),
but the lack of a signal sequence appears to prevent CNTF
from being secreted. After nerve transection, CNTF mRNA
levels decrease slightly at 1 day and drastically by 4 days in
the regions immediately surrounding the lesion site (33, 34).
CNTF protein levels only decrease slightly, however, and the
protein is thought to be present in significant quantities in the
extracellular space (34). The strong early induction in CDF/
LIF mRNA suggests that this factor may be available very
soon after damage, and this cytokine is known to be secreted
(11, 12). CDF/LIF could act on macrophages that express the
receptor for CDF/LIF (35) and invade degenerating nerve.
CDF/LIF presumably also acts on the axons, inducing
events that lead to changes in neuropeptide expression in the
neuronal cell bodies (13).
The decrease in expression of the ligand binding subunit of
the receptor complex, LIFR, in response to in vitro and in
vivo injury is puzzling. If the decrease in LIFR mRNA
expression in ganglia results in lower protein levels, then
there would be potentially fewer binding sites for CDF/LIF.
We (15) and others (36) have shown that both LIFR and gpl3O
are expressed in the neurons of sympathetic and sensory
ganglia. This would indicate that the increased CDF/LIF
produced in response to injury binds to receptors on the
neurons to induce neuropeptide expression. Ifthere are fewer
ligand binding sites, then this increased CDF/LIF may not be
as effective. In the transected sciatic nerve, the decrease in
LIFR mRNA in the region surrounding the transection site
continues for several days. The LIFR mRNA we are mea-
suring in the nerve is expressed in the nonneuronal cells and
whether a similar decrease is also occurring in the glia of the
ganglia is not known.
Although CDF/LIF alters neuropeptide synthesis in SCG
cultures, the cellular localization of the cytokine in ganglia
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LIF mRNA in cultured ganglia and nerve gave us the
opportunity to define the cell type that expresses the cyto-
kine. As was suggested (11), expression is prominent in
nonneuronal cells. The morphology of the digoxigenin-
labeled cells in the nerve resemble that of Schwann cells.
Although we cannot rule out the possibility that another cell
type, such as fibroblasts or macrophages, accounts for some
of the staining, two lines of evidence suggest that the CDF/
LIF-positive cells are glia. (i) There is a large postnatal
increase in the glial cell population in sympathetic ganglia,
and we have shown here that there is an enormous difference
in the induction of CDF/LIF mRNA in adult vs. neonatal
SCGs when the ganglia are placed in organ culture. (ii) When
injured nerve and ganglia are stained with antibodies to the
macrophage-specific marker MUC-102 in conjunction with in
situ hybridization to CDF/LIF, the macrophage-positive
cells do not colocalize with the CDF/LIF-positive cells. It is
interesting to note that the CDF/LIF-positive cells in the
ganglia are not the same size as those seen in the nerve.
CDF/LIF has been shown to be involved in the response
to trauma and infection. This cytokine causes the induction
ofacute-phase proteins in liver cells (37). It is rapidly induced
in bronchoalveolar fluid in response to lipopolysaccharide
injection (T. R. Ulich, M.-J. Fann, P.H.P., J. Williams, B.
Samal, J. delCastillo, S. Yin, K. Guo, and D. G. Remick,
unpublished data), and it is present at elevated levels in
synovial fluids in patients with arthritis (38). The demonstra-
tion of the dramatic induction of CDF/LIF in response to
nervous system trauma provides further evidence for the role
of this protein in the response to tissue damage.
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